RxDoctor Payments Data

Betty Sanchez Catanese, MD

Internal Medicine · Somerville, NJNPI 1821055450

Payments from drug & device makers

$2,089in general payments, 2019–2025

Across 146 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$304
  • AstraZeneca$278
  • AbbVie$246
  • Lilly USA, LLC$184
  • Novartis$177
  • Pfizer$173
  • plus $726 from 16 others

What the payments were for

  • Food & beverage$2,089100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,089 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$153,712
Medicare patients
306
Services billed
2,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$149,394
JardianceEmpagliflozin76$86,454
TrulicityDulaglutide37$56,216
XareltoRivaroxaban35$46,412
FarxigaDapagliflozin Propanediol36$46,142
OzempicSemaglutide23$34,347
RybelsusSemaglutide15$33,463
ProliaDenosumab18$30,744
MounjaroTirzepatide24$25,355
Breo ElliptaFluticasone/Vilanterol31$24,379
JanuviaSitagliptin Phosphate17$15,343
Spiriva HandihalerTiotropium Bromide22$13,823
SynthroidLevothyroxine Sodium114$10,966
EntrestoSacubitril/Valsartan13$9,809
NexletolBempedoic Acid14$9,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro$173$152,235133 claims
Lilly USA, LLCTrulicity, Mounjaro$184$81,57161 claims
Novo NordiskOzempic, Rybelsus$304$67,81038 claims
Johnson & JohnsonXarelto$73$46,41235 claims
AstraZenecaFarxiga$278$46,14236 claims
AmgenProlia$39$30,74418 claims
GSKBreo Ellipta$42$24,37931 claims
MerckJanuvia$104$15,34317 claims
AbbVieSynthroid$246$10,966114 claims
NovartisEntresto$177$9,80913 claims
Esperion Therapeutics, Inc.Nexletol$30$9,74214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Somerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →